Clinical trial / 2016
Flaxseed added to lifestyle modification improved liver markers in fatty liver disease
In an open-label trial with 50 adults having non-alcoholic fatty liver disease, participants received either lifestyle changes alone or with 30 grams daily of milled flaxseed for 12 weeks. Both groups improved, but flaxseed produced greater reductions in ALT (-11.12 vs -3.7 U/L), AST (-8.29 vs -4 U/L), GGT (-15.7 vs -2.62 U/L), fibrosis (-1.26 vs -0.77 kPa), and steatosis (-47 vs -15.45 dB/m). Body weight and insulin resistance also decreased more with flaxseed.
- Study type
- Randomized controlled trial
- Who was studied
- 50 patients with non-alcoholic fatty liver disease
- What was measured
- Liver enzymes, hepatic fibrosis and steatosis, body weight, insulin resistance
THE PAPER
Flaxseed supplementation in non-alcoholic fatty liver disease: a pilot randomized, open labeled, controlled study.
Yari Z, Rahimlou M, Eslamparast T, Ebrahimi-Daryani N, Poustchi H, Hekmatdoost A. Int J Food Sci Nutr, 2016.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.